Related Experiment Video
Updated: Jan 22, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
The Involvement of Pregnane X Receptor-regulated Pathways in the Antitumor Activity of Cisplatin
Megumi Yasuda1, Shuichi Kishimoto2, Manabu Amano1
1Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
Background/Aim:
Nuclear receptors regulate the expression of cellular transporters, which may be contributing factors for cisplatin (CDDP) resistance. This study aimed to clarify whether nuclear receptor ligands could be potentially used as drugs to overcome CDDP resistance.
Materials And Methods:
Caspase-3 activity was measured using a fluorogenic substrate. mRNA levels were determined using real-time polymerase chain reaction.
Results:
Pregnane X receptor (PXR) showed an expression level change dependent on caspase-3 activation by CDDP in HepG2. Rifampicin, a PXR agonist, reduced the accumulation of CDDP and suppressed growth inhibition and caspase-3 activation in HepG2 after CDDP exposure. Leflunomide, a PXR antagonist, significantly enhanced caspase-3 activation by CDDP in HepG2 and CDDP-resistant HepG2/R.
Conclusion:
These results suggest that PXR can modify the antitumor activity of CDDP, presumably through regulating the expression of transporters, which control intracellular CDDP concentration. Thus, PXR antagonists can be further investigated as potential drugs capable of overcoming CDDP resistance.
Insights
Nuclear receptors, like pregnane X receptor (PXR), influence cisplatin resistance. PXR antagonists show promise in overcoming this resistance by enhancing chemotherapy
Area of Science:
- Pharmacology
- Molecular Biology
- Cancer Research
Background:
- Nuclear receptors regulate cellular transporters, potentially contributing to cisplatin (CDDP) resistance.
- Understanding these mechanisms is crucial for developing strategies to overcome treatment failure.
Purpose of the Study:
- To investigate if nuclear receptor ligands can be used as drugs to overcome CDDP resistance.
- To explore the role of pregnane X receptor (PXR) in CDDP resistance.
Main Methods:
- Caspase-3 activity was measured using fluorogenic substrates.
- mRNA levels were quantified via real-time polymerase chain reaction (PCR).
Main Results:
- Pregnane X receptor (PXR) expression changed with CDDP-induced caspase-3 activation in HepG2 cells.
- Rifampicin (PXR agonist) decreased CDDP accumulation and inhibited growth and caspase-3 activation.
- Leflunomide (PXR antagonist) significantly enhanced CDDP-induced caspase-3 activation in HepG2 and CDDP-resistant HepG2/R cells.
Conclusions:
- PXR modulates CDDP's antitumor activity, likely by regulating transporter-mediated intracellular CDDP concentration.
- PXR antagonists represent a potential therapeutic strategy for overcoming CDDP resistance.
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
GTPases and their Regulation
Large G-proteins,...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Enteric Nervous System: Regulation of GI Motor Activity
During periods of fasting, the ENS initiates the migrating myoelectric complex, a...
GPCRs Regulate Adenylyl Cylase Activity
Epigenetic Regulation

